CAMP4 Therapeutics Announces Second Closing of $100 Million Private Placement
Rhea-AI Summary
CAMP4 Therapeutics (Nasdaq: CAMP) closed the second tranche of its previously announced $100 million private placement, raising approximately $50.1 million in gross proceeds. The financing comprised 10,756,498 common shares at $1.53, 39,306 common shares to insiders at $1.65, and 21,925,368 pre-funded warrants at $1.5299 each.
According to CAMP4 Therapeutics, net proceeds will support advancement of CMP-002, including a planned Phase 1/2 trial in SYNGAP1-related disorder in Australia, and ongoing development of its early-stage pipeline. The round included several institutional investors and was led by Leerink Partners as placement agent.
Positive
- $50.1 million gross proceeds from second closing of private placement
- Issuance of 10.76 million common shares plus 21.93 million pre-funded warrants provides capital
- Net proceeds earmarked to advance CMP-002 and early-stage pipeline programs
- Participation by multiple institutional investors, including Coastlands Capital and Janus Henderson
- Recent regulatory clearance in Australia to initiate Phase 1/2 trial in SYNGAP1-related disorder
Negative
- Equity financing entails potential dilution from 10.8 million new shares and 21.9 million pre-funded warrants
- Securities sold in an unregistered private placement, limiting immediate resale without registration or exemption
News Explained
Pre-funded warrants can convert into common shares, so existing holders’ percentage ownership can decline if they are exercised.
The completed second closing adds
A private placement sells securities to selected investors outside a public offering. These securities were not registered, so resale is limited to an effective registration statement or an exemption; the release says investors received resale registration rights for shares issuable upon warrant exercise.
Key Figures
Previous Private placement Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Sep 10 | private placement | Positive | +40.2% | Oversubscribed financing offered initial proceeds and milestone-linked additional capital. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
The only tag-matched precedent was followed by a 40.2% 24-hour increase.
Key Terms
private placement financial
pre-funded warrants financial
resale registration rights regulatory
Form 8-K regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
Proceeds of
CAMBRIDGE, Mass., Aug. 04, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4" or "the Company") (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced the closing of the second tranche of its previously announced private placement pursuant to a securities purchase agreement, dated September 9, 2025, with certain institutional and accredited investors.
In connection with the second closing, the Company received approximately
Investors that participated in the second closing include Coastlands Capital, Janus Henderson Investors, Balyasny Asset Management, Vivo Capital, 5AM Ventures, Adage Capital Management LP, Trails Edge Capital Partners and CURE SYNGAP1.
Leerink Partners acted as lead placement agent in connection with the second closing. Piper Sandler & Co., Cantor Fitzgerald & Co. and Wedbush Securities Inc. acted as co-placement agents.
The securities offered in the private placement, including the shares underlying the pre-funded warrants, were sold in a transaction not involving a public offering and have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or under any applicable state securities laws. Accordingly, the securities may not be reoffered or resold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. The investors have been granted customary resale registration rights for the shares of common stock issuable upon exercise of the pre-funded warrants issued to them in the financing.
This press release shall not constitute an offer to sell or a solicitation of an offer to purchase the securities described herein, nor shall there be any sale of such securities in any jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.
For further information, please see the Company’s current report on Form 8-K to be filed with the SEC.
About SYNGAP1-Related Disorder
SYNGAP1-related disorder (also referred to as SYNGAP1) is a rare, haploinsufficient CNS disorder caused by mutations in the SYNGAP1 gene, resulting in approximately
About CMP-002
CMP-002 is CAMP4's lead investigational antisense oligonucleotide (ASO) therapeutic candidate designed to bind to a SYNGAP1-specific regRNA to increase SYNGAP1 gene expression and restore SYNGAP protein toward near wild-type levels. Administered intrathecally, CMP-002 has demonstrated dose-dependent increases in SYNGAP protein expression in patient-derived neurons, reversal of disease-relevant behavioral phenotypes in a humanized haploinsufficient mouse model, statistically significant improvement of seizure phenotypes and parameters in a chemically induced seizure mouse model, and broad brain distribution with significant SYNGAP protein upregulation in non-human primates.
About CAMP4 Therapeutics
CAMP4 is developing disease-modifying treatments for a broad range of genetic diseases where amplifying healthy protein may offer therapeutic benefits. Our approach amplifies mRNA by harnessing a fundamental mechanism of how genes are controlled. To amplify mRNA, our therapeutic ASO drug candidates target regulatory RNAs (regRNAs), which act locally on transcription factors and are the master regulators of gene expression. CAMP4's proprietary RAP Platform® enables the mapping of regRNAs and generation of therapeutic candidates designed to target the regRNAs associated with genes underlying haploinsufficient and recessive partial loss-of-function disorders, of which there are more than 1,200, in which a modest increase in protein expression may have the potential to be clinically meaningful.
Forward-Looking Statements
This press release contains forward-looking statements which involve risks, uncertainties and contingencies, many of which are beyond the control of the Company, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. All statements other than statements of historical facts contained in this press release are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements include, but are not limited to, statements regarding the Company’s planned use of proceeds from the private placement; the initiation, timing, conduct, and advancement of CMP-002 into a clinical trial; the potential therapeutic benefits of CMP-002; the Company’s regulatory, clinical and development plans; and the satisfaction of closing conditions. The forward-looking statements in this press release speak only as of the date of this press release and are subject to a number of known and unknown risks, uncertainties and assumptions that could cause the Company's actual results to differ materially from those anticipated in the forward-looking statements, including, but not limited to: the uncertainty of preclinical and clinical development, which is lengthy and expensive, and characterized by uncertain outcomes, and risks related to additional costs or delays in completing, or failing to complete, the development and commercialization of the Company's current product candidates or any future product candidates; the Company's dependence on the services of the Company's senior management and other clinical and scientific personnel, and the Company's ability to retain these individuals or recruit additional management or clinical and scientific personnel; risks related to the manufacturing of the Company's product candidates, which is complex, and the risk that the Company's third-party manufacturers may encounter difficulties in production; the Company's ability to obtain and maintain sufficient intellectual property protection for the Company's platform technology and product candidates; and other risks and uncertainties described in the section "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2025 and Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, as well as other information the Company files with the Securities and Exchange Commission. The forward-looking statements in this press release are inherently uncertain and are not guarantees of future events. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond the Company's control, you should not unduly rely on these forward-looking statements. The events and circumstances reflected in the forward-looking statements may not be achieved or occur and actual future results, levels of activity, performance and events and circumstances could differ materially from those projected in the forward-looking statements. Moreover, the Company operates in an evolving environment. New risks and uncertainties may emerge from time to time, and management cannot predict all risks and uncertainties. Investors, potential investors, and others should give careful consideration to these risks and uncertainties. Except as required by applicable law, the Company does not undertake to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Contacts
Investor Relations:
Sara Michelmore
Milestone Advisors
sara@milestone-advisorsllc.com
Media:
Sofia Bermudez
LifeSci Communications
sbermudez@lifescicomms.com
